Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2025-05-22 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
114年05月法人說明會簡報 — 179520250522M002.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation of Lotus Pharmaceutical's first quarter 2025 financial results and business updates. It includes comprehensive financial data such as revenue, EPS, gross margin, operating profit, and segment performance. It also covers business strategy, product pipeline progress, market updates, and outlook. The presence of detailed financial tables, year-over-year comparisons, and forward-looking statements typical of quarterly financial disclosures indicates this is a quarterly financial report. The document length (7,336 characters) and content depth confirm it is not a brief earnings release or a simple announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-05-22 Chinese
114年05月法人說明會簡報 — 179520250522E001.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation of Lotus Pharmaceutical's first quarter 2025 financial results, including business highlights, financial performance metrics, pipeline updates, and business outlook. It contains comprehensive financial data such as revenue, EPS, margins, and segment breakdowns, as well as strategic and operational commentary. The presence of forward-looking statements, detailed financial tables, and business strategy sections indicates this is a quarterly financial report rather than a brief earnings release or a simple announcement. The document length (9,661 characters) and content depth confirm it is a substantive financial report for a period shorter than a full fiscal year. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-05-22 Chinese
114年05月法人說明會簡報 — 179520250522M001.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed presentation dated May 21, 2025, covering Lotus Pharmaceutical's first quarter 2025 (1Q25) financial results, operational highlights, business strategy, product pipeline updates, and market outlook. It includes comprehensive financial data such as revenue, EPS, gross margin, operating profit, and segment performance, as well as forward-looking statements and strategic business updates. The presence of detailed financial tables, year-over-year comparisons, and management commentary on business and financial performance indicates this is a quarterly financial report. The document is about 7,336 characters long, which is sufficient to contain substantive financial data and analysis, not just an announcement or summary. It is not a full annual report (10-K), nor a simple earnings release (ER) which typically contains only key highlights without detailed financial statements. It is not a call transcript (CT) as there is no Q&A or conversational text. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-05-22 Chinese
114年05月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing of scheduled investor presentations (法人說明會) with details such as company code, name, date, time, location, and links to presentation materials. It includes references to online investor meetings and presentation files. There is no financial data or report content, only information about investor presentations. Therefore, this document fits the category of Investor Presentation (IP). The document length is short but contains presentation details, not just an announcement of a report, so it is not a Report Publication Announcement (RPA).
2025-05-22 Chinese
114年05月僑外投資持股
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a statistical table showing the shareholding situation of overseas and mainland China investors, including changes before and after a shareholders' meeting date. It includes detailed shareholding numbers and dates related to the shareholders' meeting but does not contain financial statements, management discussion, or report narratives. The document length is short (1081 characters) and it is a factual disclosure related to shareholding changes due to a shareholders' meeting. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to shareholder meeting outcomes and shareholding status changes.
2025-05-21 Chinese
114年第1季大陸投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of investment information related to the company's investments in mainland China, including capital amounts, investment methods, and investment income. It includes notes explaining the investment methods and accounting treatments. The document is relatively short (1440 characters) and appears to be a regulatory disclosure of investment details rather than a full financial report or announcement. There is no indication that this is an annual or interim report, audit report, or earnings release. It is a regulatory filing providing specific investment information as required by authorities, fitting best under the category of Regulatory Filings (RNS).
2025-05-13 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.